These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16528579)

  • 1. Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?
    Hansen K; Lançon C; Toumi M
    Eur J Health Econ; 2006 Mar; 7(1):19-29. PubMed ID: 16528579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
    Bartkó G; Fehér L
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.
    Hughes D; Cowell W; Koncz T; Cramer J;
    Value Health; 2007; 10(6):498-509. PubMed ID: 17970932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
    Hamann J; Leucht S; Kissling W
    Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.
    Bettinger TL; Shuler G; Jones DR; Wilson JP
    Ann Pharmacother; 2007 Feb; 41(2):201-7. PubMed ID: 17311836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian analysis of pharmacoeconomic data from a clinical trial on schizophrenia.
    Petit C; Maccario J
    Stat Med; 2003 Mar; 22(6):1025-39. PubMed ID: 12627416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methodolocical issues of naturalistic observational studies on the economic evaluation of neuroleptic treatment for schizophrenic disease].
    Kilian R; Angermeyer MC; Becker T
    Gesundheitswesen; 2004 Mar; 66(3):180-5. PubMed ID: 15088222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of schizophrenia: let's talk dollars and sense.
    Buckley PF
    Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new atypical antipsychotics: a review of pharmacoeconomic studies.
    Revicki DA
    Expert Opin Pharmacother; 2000 Jan; 1(2):249-60. PubMed ID: 11249546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

  • 19. A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
    Damen J; Thuresson PO; Heeg B; Lothgren M
    Appl Health Econ Health Policy; 2008; 6(4):189-97. PubMed ID: 19382819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.